Michael Goldstein

Michael Goldstein leads the clinical development, clinical operations, medical affairs, manufacturing and quality teams. Before Aurion Biotech, Dr. Goldstein was president and chief medical officer at Ocular Therapeutix (Nasdaq: OCUL), a developer of longer-duration therapies for patients with ophthalmic diseases. Previously, he was chief medical officer for AGTC and Eleven Biotherapeutics. He is also an assistant professor at Tufts University School of Medicine and was co-director of the Cornea, External Disease service at Tufts University/ New England Eye Center and residency director at Tufts University/New England Eye Center.